- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or refractory peripheral T-cell lymphoma
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Romidepsin – March 2026
Injection set including 1 vial powder for injection 10 mg and 2 mL solvent
Last updated
11 March 2026